[go: up one dir, main page]

MX2020013853A - Compuestos innovadores. - Google Patents

Compuestos innovadores.

Info

Publication number
MX2020013853A
MX2020013853A MX2020013853A MX2020013853A MX2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A MX 2020013853 A MX2020013853 A MX 2020013853A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
combinations
innovative compounds
antitrypsin
Prior art date
Application number
MX2020013853A
Other languages
English (en)
Inventor
John Liddle
Kate Smith
Alexis Denis
Nerina Dodic
David Lomas
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810290.5A external-priority patent/GB201810290D0/en
Priority claimed from GBGB1906708.1A external-priority patent/GB201906708D0/en
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2020013853A publication Critical patent/MX2020013853A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos, composiciones, combinaciones y medicamentos que contienen dichos compuestos y procesos para su preparación. La invención también se refiere al uso de dichos compuestos, combinaciones, composiciones y medicamentos, por ejemplo, como moduladores de alfa 1 antitripsina y para el tratamiento de enfermedades asociadas con alfa antitripsina, particularmente enfermedades del hígado.
MX2020013853A 2018-06-22 2019-06-21 Compuestos innovadores. MX2020013853A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1810290.5A GB201810290D0 (en) 2018-06-22 2018-06-22 Novel Compounds
GBGB1906708.1A GB201906708D0 (en) 2019-05-13 2019-05-13 Novel compounds
PCT/GB2019/051761 WO2019243841A1 (en) 2018-06-22 2019-06-21 Novel compounds

Publications (1)

Publication Number Publication Date
MX2020013853A true MX2020013853A (es) 2021-05-27

Family

ID=67139769

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013853A MX2020013853A (es) 2018-06-22 2019-06-21 Compuestos innovadores.
MX2025003876A MX2025003876A (es) 2018-06-22 2020-12-16 Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025003876A MX2025003876A (es) 2018-06-22 2020-12-16 Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina

Country Status (10)

Country Link
US (3) US20210276952A1 (es)
EP (1) EP3810131A1 (es)
CN (1) CN113286586A (es)
AU (2) AU2019289228B2 (es)
BR (1) BR112020026314A2 (es)
CA (1) CA3103920C (es)
IL (2) IL279526B1 (es)
MX (2) MX2020013853A (es)
SG (1) SG11202012765PA (es)
WO (1) WO2019243841A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081257A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918413D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918404D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
CA3179333A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CA3179189A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
WO2021203014A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]l ndole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
CN115916748A (zh) * 2020-04-03 2023-04-04 弗特克斯药品有限公司 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的吲哚衍生物
CA3179184A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB202009074D0 (en) 2020-06-15 2020-07-29 Z Factor Ltd Compound
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency
CN113801053B (zh) * 2021-11-01 2023-09-08 上海皓鸿生物医药科技有限公司 一种制备7-氟-2-氧代吲哚啉-4-羧酸的方法
WO2025049936A1 (en) 2023-08-31 2025-03-06 Biomarin Pharmaceutical Inc. Solid forms of n-1-(2-chloro-3-fluorophenyl)-1-hydroxypentan-2-yl)-7-fluoro-2-oxoindoline-4-carboxamide and methods of their preparation
AR133704A1 (es) 2023-08-31 2025-10-22 Biomarin Pharm Inc Compuestos y composiciones de inhibidores de la polimerización z-at muy estereoquímicamente puros y métodos para su elaboración
WO2025049929A1 (en) * 2023-08-31 2025-03-06 Biomarin Pharmaceutical Inc. Dosage forms of n-(1-(2-chloro-3-fluorophenyl)-1-hydroxypentan-2-yl)-7-fluoro-2-oxoindoline-4-carboxamide and methods of their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
JP3987963B2 (ja) 1993-03-17 2007-10-10 スリーエム カンパニー エステルー，アミド−又はメルカプトエステル−誘導分散促進剤を含むエーロゾル配合物
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US9801637B2 (en) 2006-03-13 2017-10-31 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
KR101402702B1 (ko) 2011-09-15 2014-06-05 (주)알테오젠 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도
RU2020113165A (ru) * 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
CN113801053B (zh) 2021-11-01 2023-09-08 上海皓鸿生物医药科技有限公司 一种制备7-氟-2-氧代吲哚啉-4-羧酸的方法

Also Published As

Publication number Publication date
AU2019289228B2 (en) 2024-11-14
SG11202012765PA (en) 2021-01-28
IL279526A (en) 2021-01-31
IL279526B1 (en) 2026-01-01
CA3103920A1 (en) 2019-12-26
AU2025200968A1 (en) 2025-03-06
AU2019289228A1 (en) 2021-01-21
US20210276952A1 (en) 2021-09-09
US20240400513A1 (en) 2024-12-05
IL325356A (en) 2026-02-01
CA3103920C (en) 2025-09-16
US11919856B2 (en) 2024-03-05
BR112020026314A2 (pt) 2021-03-30
CN113286586A (zh) 2021-08-20
WO2019243841A1 (en) 2019-12-26
US20220340525A1 (en) 2022-10-27
EP3810131A1 (en) 2021-04-28
MX2025003876A (es) 2025-05-02
NZ771565A (en) 2025-08-29

Similar Documents

Publication Publication Date Title
MX2020013853A (es) Compuestos innovadores.
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
DOP2018000240A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
MX389697B (es) Nuevos derivados de pirazolopirimidina.
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
CO2019014484A2 (es) Nuevos derivados de azaquinolina
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA202090448A1 (ru) Дигидрооксадиазиноны
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
EP4252755A3 (en) Therapeutic compounds
HK1257296A1 (zh) 新的化合物及其用途
EA202091003A1 (ru) Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها